We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go: Stretch investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Yolk, also known as In One Basket Limited, is a pioneering company revolutionizing the food and coffee experience for people on the move. They provide high-quality sandwiches, salads, and improved breakfast options without the premium cost, boasting five successful locations in London and three upcoming openings in the second half of 2023
days to go: TBC investment: Withheld
The Friday Beer Co. produce and sell bottled ales. They are currently selling their ale to 50+ outlets across the West Midlands. The Friday Beer Co. aim to sell to international markets by 2020.
days to go: Expired investment: £169,090
Craved is an online marketplace for food and drink. To date, they have had most success in the corporate sales and gifting market.  
days to go: Expired investment: £127,540
Craved is an ecommerce business selling British craft food and drink from independent producers all over the country.  They believe in craft, flavour and supporting the people behind the product.  The investment will be used to grow their gifting business, launch and grow the Crave Collective and develop their corporate offer and acquire new clients.

Pitch Rated

66%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £180,590
Humble Grape is a rapidly growing wine bar brand from London working with an aim to make wine socially approachable to everyone. It mostly provides organic, biodynamic and sustainably produced wines. The four sites of Humble Grape became profitable within the first six months of operations, and the revenue surpassed the forecast of the year. Within two years of operations, it has been awarded as ‘Best Wine Retailer of the Year’ by Time and Leisure and also named as 'Notable Newcomers' by The Financial Times.
days to go: Expired investment: £654,392
Lime Global is a UK-based company dedicated to becoming the most customer-focused provider of health cover. Lime argues that conventional health insurance is too expensive and overly complicated. It intends to make health insurance affordable allowing customers to buy the top-ups they want without consulting advisers or filling long questionnaires. Lime Global claims to provide customers with a cancer cover providing a lump sum and support following diagnosis, access to 'Rapid Diagnostics' to avail private diagnostic tests, and an online platform where customers and employers can book and pay for clinical services. Lime Global aspires to become a contender in the UK private healthcare market set to grow more than £8 billion. The company points out that it has secured 5 star Trustpilot reviews over the last year with zero complaints to date. They intend to use the investment to support their expansion into Small and Medium Enterprises (SMEs), mental health modules and e-pharmacies, scale customer acquisition, and support the next stage of its growth in late 2021 and early 2022.

Pitch Rated

44%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £474,838
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph